Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

By F. Greenway, K. Fujioka, Raymond A. Plodkowski, S. Mudaliar, M. Guttadauria, J. Erickson, Dennis D. Kim, E. Dunayevich. The Lancet, 2010

898 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, background): “These agents improve BP and lipids, prevent progression to diabetes during trial periods, and improve glycemic control and lipids in patients with T2D (43-60).”
Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) (2011, result): “Although most pharmaceutical obesity RCTs include BMIs ranging from 27–40, or 45 at most, this study included patients with class II and III obesity (BMI ≥35 kg/m2) without any upper BMI limit.”
A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II) (2013, background): “The effects of bupropion and naltrexone in treating addictive disorders may partly explain the increased ability of participants to control eating and avoid responding to food cravings in this study, as well as a previous study of NB32 (13).”